Carsten Bokemeyer1, Alexander Stein2, Karsten Ridwelski3, Djordje Atanackovic2, Dirk Arnold4, Ewald Wöll5, Alexis Ulrich6, Ramona Fischer7, Colin Krüger8, Christoph Schuhmacher9. 1. Department of Internal Medicine II (Hematology, Oncology, Bone Marrow Transplantation), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. c.bokemeyer@uke.uni-hamburg.de. 2. Department of Internal Medicine II (Hematology, Oncology, Bone Marrow Transplantation), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Department of Surgery, Städtisches Klinikum Magdeburg, Magdeburg, Germany. 4. Department of Medical Oncology, Tumour Biology Institute, Freiburg, Germany. 5. Department for Internal Medicine Zams, Saint Vincent Hospital Zams, Zams, Austria. 6. Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany. 7. Neovii (formerly Fresenius) Biotech GmbH, Munich, Germany. 8. Department of Surgery, Visceral, Thoracic and Vascular Surgery, Vivantes Hospital of Neukoelln, Berlin, Germany. 9. Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Abstract
BACKGROUND: Postoperative relapse rate after gastrectomy and perioperative chemotherapy remain high in patients with advanced gastric cancer due to the spread of disseminated tumour cells in the peritoneal cavity. Perioperative administration of catumaxomab could potentially eliminate residual tumour cells after intended curative resection of the primary tumour. METHODS: This open-label, phase II study investigated the safety and efficacy of catumaxomab following neoadjuvant chemotherapy and subsequent surgery in patients with resectable (T2-4, N+, M0) gastric adenocarcinoma. Patients received catumaxomab intra- (single 10 μg dose) and postoperatively (10, 20, 50 and 150 μg on days 7, 10, 13 and 16, respectively). The primary endpoint was the postoperative complication rate (maximum rate defined as <62 %) within 30 days after surgery in patients who received at least the first catumaxomab dose. RESULTS: Of 64 patients treated with neoadjuvant chemotherapy, 58 underwent surgery and 54 received at least the first catumaxomab dose. Postoperative complications were reported in 18 of 54 evaluable patients (complication rate 33 %; 95 % confidence interval: 21-48 %); thus, the primary endpoint was met. The most frequent complications were pulmonary infection (17 %) and anastomosis insufficiency requiring surgery (11 %). The most common catumaxomab-related adverse events were pyrexia (67 %), leucocytosis (19 %), abdominal pain (17 %) and chills (17 %). The 4-year disease-free and overall survival rates were 38 and 50 %. CONCLUSION: Intra- and postoperative administration of catumaxomab as part of a multimodal treatment approach was feasible and tolerable in patients with advanced gastric cancer and should be further investigated in a randomised trial.
BACKGROUND: Postoperative relapse rate after gastrectomy and perioperative chemotherapy remain high in patients with advanced gastric cancer due to the spread of disseminated tumour cells in the peritoneal cavity. Perioperative administration of catumaxomab could potentially eliminate residual tumour cells after intended curative resection of the primary tumour. METHODS: This open-label, phase II study investigated the safety and efficacy of catumaxomab following neoadjuvant chemotherapy and subsequent surgery in patients with resectable (T2-4, N+, M0) gastric adenocarcinoma. Patients received catumaxomab intra- (single 10 μg dose) and postoperatively (10, 20, 50 and 150 μg on days 7, 10, 13 and 16, respectively). The primary endpoint was the postoperative complication rate (maximum rate defined as <62 %) within 30 days after surgery in patients who received at least the first catumaxomab dose. RESULTS: Of 64 patients treated with neoadjuvant chemotherapy, 58 underwent surgery and 54 received at least the first catumaxomab dose. Postoperative complications were reported in 18 of 54 evaluable patients (complication rate 33 %; 95 % confidence interval: 21-48 %); thus, the primary endpoint was met. The most frequent complications were pulmonary infection (17 %) and anastomosis insufficiency requiring surgery (11 %). The most common catumaxomab-related adverse events were pyrexia (67 %), leucocytosis (19 %), abdominal pain (17 %) and chills (17 %). The 4-year disease-free and overall survival rates were 38 and 50 %. CONCLUSION: Intra- and postoperative administration of catumaxomab as part of a multimodal treatment approach was feasible and tolerable in patients with advanced gastric cancer and should be further investigated in a randomised trial.
Authors: G Spizzo; D Öfner; A de Vries; P Lukas; G Steger; U Pluschnig; J Zacherl; J Widder; A Zabernigg; G Gastl; G Mühlmann Journal: Ann Surg Oncol Date: 2010-11-10 Impact factor: 5.344
Authors: Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero Journal: Lancet Date: 2013-10-03 Impact factor: 79.321
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: Bella Guerrouahen; Muhammad Elnaggar; Anjud Al-Mohannadi; Dhanya Kizhakayil; Chiara Bonini; Reuben Benjamin; Renier Brentjens; Christian J Buchholz; Giulia Casorati; Soldano Ferrone; Frederick L Locke; Francisco Martin; Axel Schambach; Cameron Turtle; Paul Veys; Hans J van der Vliet; Cristina Maccalli Journal: Front Immunol Date: 2021-01-14 Impact factor: 7.561